1/8
08:00 am
prqr
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
Medium
Report
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
12/28
04:01 pm
prqr
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions [Yahoo! Finance]
Medium
Report
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions [Yahoo! Finance]
12/1
08:10 am
prqr
ProQR to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
High
Report
ProQR to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
12/1
08:00 am
prqr
ProQR to Participate in 8th Annual Evercore Healthcare Conference
High
Report
ProQR to Participate in 8th Annual Evercore Healthcare Conference
11/15
10:33 am
prqr
ProQR Therapeutics (NASDAQ:PRQR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
ProQR Therapeutics (NASDAQ:PRQR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/6
07:00 am
prqr
ProQR Announces Third Quarter 2025 Operating and Financial Results
Medium
Report
ProQR Announces Third Quarter 2025 Operating and Financial Results
11/4
08:42 am
prqr
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Medium
Report
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.